State of the art in benefit–risk analysis: Medicines-Reference-Cited by-同舟云学术

State of the art in benefit–risk analysis: Medicines

Published:2012-01 Issue:1 Volume:50 Page:26-32
ISSN:0278-6915
Container-title:Food and Chemical Toxicology
language:en
Short-container-title:Food and Chemical Toxicology

Author:

Luteijn J.M.,White B.C.,Gunnlaugsdóttir H.,Holm F.,Kalogeras N.,Leino O.,Magnússon S.H.,Odekerken G.,Pohjola M.V.,Tijhuis M.J.,Tuomisto J.T.,Ueland Ø.,McCarron P.A.,Verhagen H.

Publisher

Elsevier BV

Subject

Toxicology,General Medicine,Food Science

Reference35 articles.

1. What is the best approach to reducing birth defects associated with isotretinoin?;Abroms;PLoS Med.,2006

2. Evaluating drug effects in the post-Vioxx world: there must be a better way;Avorn;Circulation,2006

3. Economists’ dream or nightmare? Maximizing health gains from available resources using the NICE guidelines;Birch;Health. Econ. Policy. Law.,2007

4. The history of thalidomide;Botting;Drug News Perspect.,2002

5. Efficacy, effectiveness, variations, and quality;Brook;Boundary-crossing Res. Med. Care,1985

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methodological guidelines and publications of benefit–risk assessment for health technology assessment: a scoping review;BMJ Open;2024-06

2. A similarity-based deep learning approach for determining the frequencies of drug side effects;Briefings in Bioinformatics;2021-10-27

3. Risk-benefit in food safety and nutrition – Outcome of the 2019 Parma Summer School;Food Research International;2021-03

4. Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression;Clinical Pharmacology & Therapeutics;2020-10-13

5. Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit–Risk Models: The Example of Rotavirus Vaccination in France;Clinical Therapeutics;2020-10